Search Results Search Sort by RelevanceMost Recent State of the Art and Science Dec 2004 The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines Niharika P. Bansal Recent clinical trials have led to updates in the management of patients with high cholesterol. Virtual Mentor. 2004;6(12):550-553. doi: 10.1001/virtualmentor.2004.6.12.cprl1-0412. Health Law Dec 2004 What Counts as Expert Medical Testimony? Mollie E. O'Brien Medical standards of care and legal standards of reliability and relevance sometimes conflict in courtroom settings. Virtual Mentor. 2004;6(12):554-557. doi: 10.1001/virtualmentor.2004.6.12.hlaw1-0412. Medicine and Society Jul 2024 What Would Equitable Harm Reduction Look Like? Oluwole Jegede, MD, MPH, Julio C. Nunes, MD, Terence Tumenta, MD, MPH, Carmen Black, MD, and Joao P. DeAquino, MD Structural determinants of health frameworks must be person centered and express antiracism to be effective. AMA J Ethics. 2024;26(7):E572-579. doi: 10.1001/amajethics.2024.572. Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562. Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551. In the Literature Jul 2024 How Should Harm Reduction Strategies Differ for Adolescents and Adults? Brady J. Heward, MD, Amy M. Yule, MD, and Peter R. Jackson, MD Recent increases in adolescent mortality from overdose have outpaced increases in mortality in members of the general population. AMA J Ethics. 2024;26(7):E534-545. doi: 10.1001/amajethics.2024.534. Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512. Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520. History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024;26(7):E580-586. doi: 10.1001/amajethics.2024.580. Health Law Jul 2024 What Should the US Learn From New York’s and Portugal’s Approaches to the Opioid Crisis? Maura McGinnity Some US localities are trying interventions modeled on international approaches to decriminalization. AMA J Ethics. 2024;26(7):E546-550. doi: 10.1001/amajethics.2024.546. Pagination First page « First Previous page ‹ Previous … Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Current page 25 Page 26 Page 27 Next page Next › Last page Last »
State of the Art and Science Dec 2004 The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines Niharika P. Bansal Recent clinical trials have led to updates in the management of patients with high cholesterol. Virtual Mentor. 2004;6(12):550-553. doi: 10.1001/virtualmentor.2004.6.12.cprl1-0412.
Health Law Dec 2004 What Counts as Expert Medical Testimony? Mollie E. O'Brien Medical standards of care and legal standards of reliability and relevance sometimes conflict in courtroom settings. Virtual Mentor. 2004;6(12):554-557. doi: 10.1001/virtualmentor.2004.6.12.hlaw1-0412.
Medicine and Society Jul 2024 What Would Equitable Harm Reduction Look Like? Oluwole Jegede, MD, MPH, Julio C. Nunes, MD, Terence Tumenta, MD, MPH, Carmen Black, MD, and Joao P. DeAquino, MD Structural determinants of health frameworks must be person centered and express antiracism to be effective. AMA J Ethics. 2024;26(7):E572-579. doi: 10.1001/amajethics.2024.572.
Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562.
Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551.
In the Literature Jul 2024 How Should Harm Reduction Strategies Differ for Adolescents and Adults? Brady J. Heward, MD, Amy M. Yule, MD, and Peter R. Jackson, MD Recent increases in adolescent mortality from overdose have outpaced increases in mortality in members of the general population. AMA J Ethics. 2024;26(7):E534-545. doi: 10.1001/amajethics.2024.534.
Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512.
Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520.
History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024;26(7):E580-586. doi: 10.1001/amajethics.2024.580.
Health Law Jul 2024 What Should the US Learn From New York’s and Portugal’s Approaches to the Opioid Crisis? Maura McGinnity Some US localities are trying interventions modeled on international approaches to decriminalization. AMA J Ethics. 2024;26(7):E546-550. doi: 10.1001/amajethics.2024.546.